ATLANTA, GA–Sciele Pharma, Inc. (NASDAQ:SCRX) today announced the launch of Prenate DHA, a prescription multivitamin nutritional supplement with essential minerals, Omega-3 fatty acids/DHA and Metafolin, indicated for use in improving the nutritional status of women throughout pregnancy and in the postnatal period for both lactating and non-lactating mothers. Prenate DHA can also be beneficial in improving the nutritional status of women prior to conceiving.

Prenate DHA, an easy-to-swallow, soft-gel capsule, contains 365 milligrams of Omega-3 fatty acids, of which 300 milligrams are DHA from purified fish oil, the highest amount available in a prescription prenatal vitamin. This new formulation also provides nine important vitamins and minerals, including a unique 1 milligram folate combination with 400 micrograms of folic acid and 600 micrograms of Metafolin - the active form of folate, and calcium docusate, a gentle stool softener - for extra comfort during pregnancy.

Patrick Fourteau, Chief Executive Officer of Sciele, said, “We are pleased to introduce Prenate DHA, which is designed to enhance the health and well-being of mothers and their babies. Medical research has recognized the benefits of DHA to help give babies a healthier start in life. We take great satisfaction in providing the highest amounts of Omega-3 fatty acids/DHA with a combination of Metafolin and folic acid in a prescription prenatal/postnatal vitamin. Sciele is a leader in Women’s Health and Prenate DHA is an important addition to our Prenate product line, a highly recognized and trusted prescription brand of prenatal vitamins in the United States.”

The National Institutes of Health (NIH) recommends a daily dose of 300 milligrams of DHA during pregnancy. Since many women do not get the DHA they need from diet alone, a prescription prenatal vitamin with DHA provides a benefit to the baby’s development and the mother’s health and well-being.

www.sciele.com